Marsupial Pouch Houses Surgical Drainage Tubes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 6
Volume 7
Issue 6

PRINCETON, NJ--The Marsupial Pouch, designed to help women cope with temporary surgical drains following breast surgery, is being distributed nationwide by Derma Sciences Inc. Designed by a two-time breast cancer survivor, the product is an adjustable terry cloth belt with an attachable pouch to house the drainage tubes.

PRINCETON, NJ--The Marsupial Pouch, designed to help women cope with temporary surgical drains following breast surgery, is being distributed nationwide by Derma Sciences Inc. Designed by a two-time breast cancer survivor, the product is an adjustable terry cloth belt with an attachable pouch to house the drainage tubes.

The pouch provides an alternative to using pins or tape to attach the surgical drains to undergarments. Women wear the pouch under their clothes, freeing their hands to perform daily living tasks. "Without the Marsupial Pouch, you are forced to hold the tube in one hand, making it extremely difficult to shower or perform any task of daily living," said the developer Nancy Turner.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.